Cardiovascular Disease

Choline Fenofibrate (Standard) is the analytical standard of Choline Fenofibrate. This product is intended for research and analytical applications. Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect.

Lidocaine-d₆ (Lignocaine-d₆) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.

DPCPX-d₄ (PD 116948-d₄) is deuterium-labeled DPCPX (HY-100937).

Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cladribine-¹⁵N (2-Chloro-2′-deoxyadenosine-¹⁵N) is ¹⁵N labeled Cladribine. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.

SCH-34826 is an orally active neutral metalloendopeptidase (NEP) inhibitor that inhibits NEP and reduces the degradation of ANF, thereby enhancing its antihypertensive and diuretic effects. SCH-34826 can be used in the research of cardiovascular and renal diseases.

CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.

Atreleuton-d₄ (ABT-761-d₄; VIA-2291-d₄) is deuterium-labeled Atreleuton (HY-117853).

Baogongteng A ((-)-Bao Gong Teng A) is an optically active tropane alkaloid with hypotensive and miotic activity, and can be isolated from the Chinese herb Erycibe obtusifolia Benth. Baogongteng A is also a muscarinic agonist. Baogongteng A can be used for cardiovascular and glaucoma research.

GRL-098-22 (Compound 6t) is a potent inhibitor targeting G protein-coupled receptor kinase 5 (GRK5) and GRK6 with IC₅₀ values of 0.6 μM and 0.19 μM, respectively. GRL-098-22 is promising for research of diseases such as heart failure and multiple myeloma.

Methyl maslinate is a β-adrenergic antagonist. Methyl maslinate is a potent cardiotonic and antidysrhythmic agent. Methyl maslinate has the potential for hypertension research.

WIZ degrader 5 (example 41) is a molecular glue degrader for widely interspaced zinc (WIZ) finger motifs with an AC₅₀ of 0.14 nM. WIZ degrader 5 induces the expression of fetal hemoglobin (HbF) with an EC₅₀ of 25 nM. WIZ degrader 5 can be used in research related to hereditary blood disorders, such as sickle cell disease (SCD) and thalassemia.

Yoda 1 (Standard) is the analytical standard of Yoda 1 (HY-18723). This product is intended for research and analytical applications. Yoda 1 is a potent and selective Piezo1 agonist. Yoda 1 activates purified Piezo1 channels. Yoda 1 potently inhibits macropinocytosis induced by epidermal growth factor (EGF). Yoda 1 enhances Ca²⁺ influx followed by activation of the calcium-activated potassium channel KCa3.1 and inhibition of Rac1 activation.

BMS-191095 hydrochloride is a mitochondrial K_ATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.

Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC₅₀=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.

Ap3A is a vasoactive molecule that regulates intracellular Ca²⁺ levels. Ap3A can promote the growth of vascular smooth muscle cells.

Metoprolol Hydrochloride is an orally active and selective β1-adrenoceptor antagonist. Metoprolol Hydrochloride exhibits anti-inflammatory, antitumor, and anti-angiogenic properties.

Fluvastatin (Standard) is the analytical standard of Fluvastatin. This product is intended for research and analytical applications. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

GSK484 (hydrochloride) (Standard) is the analytical standard of GSK484 (hydrochloride) (HY-100514). This product is intended for research and analytical applications. GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.

AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis.